Results 11 to 20 of about 7,183 (232)

Trail Toward Tenecteplase

Annals of Indian Academy of Neurology, 2022
Trilochan Srivastava, Neetu Ramrakhiani, Vikram Bohra   +2 more
openalex   +4 more sources

Comparative effectiveness and safety of tenecteplase versus alteplase for intravenous thrombolysis in acute ischemic stroke: a retrospective study [PDF]

Frontiers in Neurology
BackgroundTenecteplase has been proposed as a practical alternative to alteplase for intravenous thrombolysis in acute ischemic stroke. Although randomised trials have demonstrated noninferiority, data from real-world comparative cohorts remain limited ...
Weili Zhao, Xi Zhang, Yang Zhao, Ruijie Zhao, Yalin Liu   +4 more
doaj   +2 more sources

Tenecteplase versus alteplase for acute ischemic stroke. [PDF]

Cochrane Database Syst Rev
Prabhakar H, Kapoor I, Mahajan C, Kukanti C, Kalaivani M.   +4 more
europepmc   +3 more sources

Tenecteplase for Ischemic Stroke due to Large Vessel Occlusion at 4.5 to 24 Hours: A Meta-Analysis of Randomized Controlled Trials. [PDF]

Brain Behav
Question: Is it safe and effective to use tenecteplase for acute ischemic stroke patients beyond 4.5 h? Finding: This meta‐analysis of randomized controlled trials manifested that tenecteplase administered within 4.5 to 24 h for large vessel occlusion stroke was superior to control for an excellent functional outcome without safety concerns.
Wu S, Wang L, Cao Z, Hao M, Wu N, Shen K, Tang Y, Zhang Y, Ma Y, Li Z, Xiong Y.   +10 more
europepmc   +2 more sources

European Stroke Organisation (ESO) expedited recommendation on tenecteplase for acute ischaemic stroke [PDF]

European Stroke Journal, 2023
Sonia Alamowitch, Guillaume Turc, Lina Palaiodimou   +2 more
exaly   +2 more sources

Abstract 082: Outcomes of Tenecteplase vs Alteplase in Acute Telestroke Care

Stroke Vasc Interv Neurol
Hall N, Figurelle M, McCoy M, Gao L, Mayer L, Sevilis T.   +5 more
europepmc   +2 more sources

Prospective Observational Cohort Study of Tenecteplase Versus Alteplase in Routine Clinical Practice [PDF]

Stroke, 2022
Steven J Warach, Adrienne N Dula, Truman J Milling   +2 more
exaly   +2 more sources

Tenecteplase, 0.4 mg/kg, in Moderate and Severe Acute Ischemic Stroke: A Pooled Analysis of NOR‐TEST and NOR‐TEST 2A

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2023
Background The optimal dose of tenecteplase in acute ischemic stroke remains to be defined. We present a pooled analysis of the 2 NOR‐TESTs (Norwegian Tenecteplase Stroke Trials) exploring the efficacy and safety of tenecteplase, 0.4 mg/kg.
Vojtech Novotny, Christopher Elnan Kvistad, Halvor Naess, Nicola Logallo, Annette Fromm, Andrej Netland Khanevski, Lars Thomassen   +6 more
doaj   +1 more source

Simultaneous Intracranial and Spinal Hemorrhage Following Tenecteplase Thrombolysis for ST‐Elevation Myocardial Infarction: A Case Report [PDF]

Clin Case Rep
ABSTRACT Central nervous system (CNS) hemorrhage is a serious complication of intravenous thrombolysis. Tenecteplase, a fibrin‐specific thrombolytic agent, has a lower risk of hemorrhage than other agents. We report the first documented case of simultaneous intracranial and spinal hemorrhage following intravenous administration of tenecteplase.
Palliyaguru T, Ruwanpathirana P, Weeratunga P, Aravinthan M, Chang T.   +4 more
europepmc   +2 more sources

Abstract 267: A Bibliometric Analysis of Tenecteplase Research Utilizing a Commonly Used Citation Index

Stroke: Vascular and Interventional Neurology, 2023
Introduction Tenecteplase is increasingly being used as a first‐line treatment for acute ischemic stroke after several randomized studies demonstrated its safety and efficacy, resulting in a massive increase in the number of published studies on this ...
Brendan Huang
doaj   +1 more source